Explore Regeneron’s clinical pipeline. Our pipeline is powered by end-to-end research and development capabilities, and our portfolio of investigational medicines reflects the true collaborative spirit of Regeneron. The Research team discovers promising new drug candidates.

Regeneron-invented approved medicines. At Regeneron, our goal is to address serious medical conditions across multiple and diverse therapeutic areas. Our approved and authorized medicines are only the beginning of our long-term commitment to solve …

TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy...

Jan 31, 2024 · Regeneron Pharmaceuticals has formed Regeneron Cell Medicines, a new research and development (R&D) unit focused on advancing cell therapies in oncology and immunology.

Jan 30, 2024 · The experimental cell therapies Regeneron acquires will be housed in a newly created research and development unit called Regeneron Cell Medicines, to be led by 2seventy’s top scientist Phil Gregory. Approximately 150 staff …

Genetic medicines allow Regeneron to pursue important targets and programs beyond what we can with antibodies alone. We are advancing best-in-class genetic medicine technologies by applying our existing industry-leading technology platforms, like VelociSuite®.

On Jan. 30, 2024, Regeneron Pharmaceuticals (Regeneron) announced the formation of a new R&D unit, Regeneron Cell Medicines, founded on an agreement with 2seventy bio, a US-based immuno-oncology cell therapy company.

We are seeking an enthusiastic Manufacturing Specialist to join our successful internal manufacturing team as part of our broader Regeneron Cell Medicines (RCM) group. You will contribute your cell therapy manufacturing expertise in process operations, documentation and review, material safety, compliance, and directly support the advancement of our clinical portfolio. We hope you are excited ...

Jan 30, 2024 · To realize the full potential of these programs and capabilities, Regeneron Cell Medicines has been created to advance the next generation of cell therapies and explore combinations with...

Jan 30, 2024 · Regeneron will fully acquire 2seventy’s dual-targeted CAR T cell therapy bbT369 in B-cell non-Hodgkin lymphoma, SC-DARIC33 in acute myeloid leukemia, MUC16 for ovarian cancer, MAGE-A4, autoimmune...